SFGP
ACAD icon

Stonebridge Financial Group (Pennsylvania)’s Acadia Pharmaceuticals ACAD Stock Holding History

Stonebridge Financial Group (Pennsylvania)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60
Closed -$997 – 239
2025
Q1 		$997 Hold
60
– – ﹤0.01% 822
2024
Q4 		$1.1K Buy
+60
New +$968 ﹤0.01% 772

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Stonebridge Financial Group (Pennsylvania)'s ACAD Position: Q2 2025 in Review

Stonebridge Financial Group (Pennsylvania) sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 60 shares — an estimated $997 sold.

Stonebridge Financial Group (Pennsylvania) first reported a position in ACAD in Q4 2024 and held it in 2 quarters. The position peaked at $1.1K in Q4 2024. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

  • Stonebridge Financial Group (Pennsylvania) reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stonebridge Financial Group (Pennsylvania) sold 60 Acadia Pharmaceuticals shares in Q2 2025, an estimated $997.
  • Stonebridge Financial Group (Pennsylvania) first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Stonebridge Financial Group (Pennsylvania)'s Acadia Pharmaceuticals position peaked at $1.1K in Q4 2024.
  • 311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Stonebridge Financial Group (Pennsylvania)'s 13F filing for Q2 2025, filed 24 Jul 2025.